Cutaneous extranodal NK/T-cell lymphoma: A clinicopathologic study of 5 patients with array-based comparative genomic hybridization

Blood

Volumn 116, Issue 2, 2010, Pages 165-170

  Berti, Emilio ^a   Recalcati, Sebastiano ^b   Girgenti, Valentina ^b   Fanoni, Daniele ^b   Venegoni, Luigia ^b   Vezzoli, Pamela ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANCICLOVIR; GANCICLOVIR PLUS BUTYRIC ACID; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE STUDY; CAUCASIAN; CHROMOSOME 12P; CHROMOSOME 12Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 7Q; CHROMOSOME 9P; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CUTANEOUS T CELL LYMPHOMA; ERYTHEMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIMB; LOSS OF FUNCTION MUTATION; MALE; MULTIMODALITY CANCER THERAPY; NK T CELL LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SKIN NODULE; SKIN ULCER; SURVIVAL RATE; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MORTALITY; NATURAL KILLER T CELL; PATHOLOGY; SKIN TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; SKIN NEOPLASMS;

EID: 77955482964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-252957     Document Type: Article

References (29)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:285-288.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9(7):717-720.
3. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16(2):206-214.
4. Choi YL, Park JH, Namkung JH, et al. Extranodal NK/T-cell lymphoma with cutaneous involvement: 'nasal' vs. 'nasal-type' subgroups - a retrospective study of 18 patients. Br J Dermatol. 2009;160(2):333-337.
5. Stokkermans-Dubois J, Jouary T, Vergier B, Delaunay MM, Taieb A. A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature. Dermatology. 2006;213(4):345-349. (Pubitemid 44837026)
6. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol. 2007;60(9):981-989.
7. Pagano L, Gallamini A, Trapè G, et al. Intergruppo Italiano Linfomi. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol. 2006;17(5):794-800.
8. Yu JB, Zuo Z, Tang Y, et al. Extranodal nasal-type natural killer/T-cell lymphoma of the skin: a clinicopathologic study of 16 cases in China. Hum Pathol. 2009;40(6):807-816.
9. Au WY, Weisenburger DD, Intragumtornchai T, et al; International Peripheral T-Cell Lymphoma Project. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931-3937.
10. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17(9):1097-1107.
11. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41(10):1402-1408.
12. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-221.
13. Schwartz EJ, Molina-Kirsch H, Zhao S, Marinelli RJ, Warnke RA, Natkunam Y. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases. Am J Clin Pathol. 2008;130(3):343-351.
14. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
15. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1861.
16. Hermans J, Krol AD, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995;86(4):1460-1463.
17. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed, vol 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
18. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21(5):1032-1040.)
19. Lim ST, Hee SW, Quek R, et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008;80(1):55-60.
20. Kim K, Chie EK, Kim CW, Kim IH, Park CI. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol. 2005;35(1):1-5. (Pubitemid 40450547)
21. Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant. 2003;31(2):105-111. (Pubitemid 36240501)
22. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130(4):561-567.
23. Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol. 2009;147(1):13-21.
24. Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44(3):247-255.
25. Ko YH, Choi KE, Han JH, Kim JM, Ree HJ. Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma. Cytometry. 2001;46(2):85-91.
26. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23(6):1139-1151.
27. Van Kester MS, Tensen CP, Vermeer MH, et al. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol. 2010;130(2):563-575.
28. Senff NJ, Zoutman WH, Vermeer MH, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129(5):1149-1155.
29. Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest. 2000;80(4):493-499. (Pubitemid 30226631)